Patent intelligence · US
US 12043640
Prodrugs of STAT3 inhibitors
Prodrugs of STAT3 inhibitors
Patent details — US 12043640
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 23, 2024
- Expiration
- Jul 18, 2044
- Applicant
- Tvardi Therapeutics, Inc.
- Claims
- 14
- CPC classes
- A61P, A61P35/00
Quick answer
US 12043640 (Prodrugs of STAT3 inhibitors) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Jul 23, 2024. Expires Jul 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tvardi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61P, A61P35/00
More from Tvardi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12043640?
US 12043640 (Prodrugs of STAT3 inhibitors) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Jul 23, 2024. Expires Jul 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12043640?
Tvardi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12043640 expire?
Our index shows an expiration date of Jul 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.